China (Mainland)
Tigecycline CAS NO.220620-09-7
- Min.Order: 10 Gram
- Payment Terms: L/C,T/T,Other
- Product Details
Keywords
- Tigecycline
- Tigecycline price
- 220620-09-7
Quick Details
- ProName: Tigecycline
- CasNo: 220620-09-7
- Molecular Formula: C29H39N5O8
- Appearance: White powder
- Application: Used as pharmaceutical intermediates
- DeliveryTime: within 1-10 working days
- PackAge: Aluminous bag
- Port: Shanghai or Any China port
- ProductionCapacity: 10000 Kilogram/Day
- Purity: 99%
- Transportation: By Sea or By Air
- LimitNum: 10 Gram
Superiority
Shanghai LONGBANG , Boasts strong competitive advantages by our well-trained chemists with rich professional backgroud. We aim to win the market via quick response and fast delivery, as well as continous development for high-tech medical compounds, bio-medicine, and new pharmaceutical intermediates.
- Our quality assurance system is based on GMP.
- Products are exported to all over the world: USA, Europe, South Asia, Middle East and so on, also has established long term and stable business relationships with our customers.
- Fast delivery
- High quality, Preferential price
Details
ProName: Tigecycline
Protein binding:71-89%
Metabolism:not metabolised
Half-life:42.4 hours
Excretion:59% biliary, 33% renal
CAS number:220620-09-7
ATC code:J01AA12
PubChem:CID 5282044
DrugBank:DB00560
ChemSpider:10482314
UNII:70JE2N95KR
KEGG:D01079
Formula:C29H39N5O8
Mol. mass:585.65 g/mol
Synonyms:N-[(5aR,6aS,7S,9Z,10aS)-9-(amino-hydroxy-methylidene)-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-2-(tert-butylamino)acetamide
IUPAC:N-[(5aR,6aS,7S,9Z,10aS)-9-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5,5a,6,6a,7,8,9,10,10a,11-decahydrotetracen-2-yl]-2-(tert-butylamino)acetamide
Product information:
Tigecycline is the first drug in the glycylcycline class of antibiotics. Although it is structurally related to minocycline, alterations to the molecule resulted in its expanded spectrum of activity and decreased susceptibility to the development of resistance when compared with other tetracycline antibiotics. Tigecycline has a broad spectrum of activity, including activity against drug-resistant gram-positive organisms. Randomized trials have shown tigecycline to be efficacious for the treatment of complicated intraabdominal infections and complicated skin and skin structure infections. The dose of tigecycline is 50 mg intravenously every 12 hours after a 100-mg loading dose. Nausea, vomiting, and diarrhea were the most common adverse events reported with tigecycline therapy and may result in discontinuation of therapy.
Email: maggie@longbangsy.com